CD274 and neoplasm: Anti-PD therapy was developed based on early findings showing selective upregulation of B7-H1 in the tumor microenvironment (TME) by IFN-γ, leading to dysfunction of tumor-infiltrating T lymphocytes (TILs) upon its engagement of PD-1, a mechanism called adaptive immune resistance (18, 19, 21, 22).